Petros Family Wealth LLC Has $640,000 Stock Position in Pfizer Inc. $PFE

Petros Family Wealth LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 22.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,406 shares of the biopharmaceutical company’s stock after selling 7,779 shares during the quarter. Petros Family Wealth LLC’s holdings in Pfizer were worth $640,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Northern Trust Corp lifted its position in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares during the period. Amundi lifted its position in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Invesco Ltd. lifted its position in shares of Pfizer by 2.8% in the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock worth $767,709,000 after acquiring an additional 838,198 shares during the period. Finally, Deutsche Bank AG lifted its position in shares of Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock worth $715,581,000 after acquiring an additional 1,846,436 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.1%

Shares of PFE opened at $27.37 on Monday. The stock has a fifty day moving average price of $24.67 and a two-hundred day moving average price of $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.